OP05 efficiency frontier analysis of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma in Brazil

Página do item simplificado
dc.creatorMarcus Carvalho Borin
dc.creatorLudmila Peres Gargano
dc.creatorÁlex Brunno do Nascimento Martins
dc.creatorBárbara Rodrigues Alvernaz dos Santos
dc.creatorIsabela Freitas
dc.creatorFrancisco de Assis Acurcio
dc.creatorJuliana Alvares Teodoro
dc.creatorAugusto Afonso Guerra Júnior
dc.date.accessioned2026-01-20T19:36:09Z
dc.date.issued2025-01-07
dc.descriptionPôster apresentado no HTAi 2024, encontro que ocorreu em Sevilha, na Espanha.
dc.identifier.doihttps://doi.org/10.1017/S0266462324000692
dc.identifier.issn1471-6348
dc.identifier.urihttps://hdl.handle.net/1843/1443
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofInternational Journal of Technology Assessment in Health Care
dc.rightsAcesso aberto
dc.subjectNeoplasia
dc.subject.otherMieloma múltiplo
dc.titleOP05 efficiency frontier analysis of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma in Brazil
dc.typeArtigo de periódico
local.citation.issue1
local.citation.volume40
local.description.resumoIntroduction Multiple myeloma (MM) is a challenging hematological malignancy, primarily treated with autologous stem cell transplantation (ASCT). However, relapse or refractoriness is inevitable, necessitating alternative treatments. This study evaluates ciltacabtagene autoleucel (Carvykti®), a novel therapy, against a second ASCT, using an efficiency frontier approach to assess its therapeutic value and cost-effectiveness. Methods We conducted a comparative analysis using data from CARTITUDE-1 clinical trials and a Brazilian real-world cohort (2002 to 2015) of MM patients treated under SUS (Brazilian Healthcare System). We estimated survival curves and area under the curve (AUC) for both interventions over 48 months and projected the curves for a 10-year horizon using parametric distributions. Cost-effectiveness was assessed by calculating the incremental cost per month of survival. Efficiency frontier methodology was employed to determine a proportional price for ciltacabtagene autoleucel, based on the cost and median survival benefits compared to the second ASCT. Results Ciltacabtagene autoleucel demonstrated a 7.27 percent increase in AUC for overall survival over 48 months compared to the second ASCT. The incremental cost was BRL54,219.15 (USD11,133.30) per month of survival. Over a 10-year horizon, the estimated cost for ciltacabtagene autoleucel was significantly higher than that for the second ASCT. Using the efficiency frontier approach, the cost of ciltacabtagene autoleucel should not exceed BRL228,226.42 (USD46,863.74), considering its survival benefit and cost of production. Conclusions Ciltacabtagene autoleucel demonstrates significant anti-tumor activity in relapsed/refractory MM, with a notable survival advantage. Efficiency frontier analysis suggests a maximum justified cost, providing a framework for pricing decisions. This study highlights the importance of balancing innovation with cost-effectiveness in healthcare decision-making.
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIAL
local.publisher.initialsUFMG
local.subject.cnpqCIENCIAS DA SAUDE
local.url.externahttps://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/op05-efficiency-frontier-analysis-of-ciltacabtagene-autoleucel-for-relapsedrefractory-multiple-myeloma-in-brazil/AE957C70390C112D7D09185E62E5DC1D

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Op05 efficiency frontier analysis of ciltacabtagene autoleucel for relapsed refractory multiple myeloma in brazil.pdf
Tamanho:
32.08 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
license.txt
Tamanho:
2.07 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG